



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): DALTON, James T., et al EXAMINER: Not yet known

SERIAL NO.: 10/616,500 GROUP ART UNIT: Not yet known

FILED: July 10, 2003

FOR: IMPROVED PIPE REPAIR CLAMP

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes Form PTO-1449:

1. listing documents including patents, publications and other information for consideration by the Examiner, however, since the subject application was filed after June 30, 2003, copies of United States patents, and/or United States patent applications, and/or United States patent application publications are not included in this information disclosure statement; and/or
2. listing documents including patents, publications and other information that have been previously cited or submitted to the Patent Office in prior application U.S. Serial No. 10/371,211, filed February 24, 2003 which is properly identified and relied on for an earlier effective filing date under 35 U.S.C. 120 for consideration by the Examiner; however, in accordance with 37 C.F.R. 1.98(d), copies of such documents are not included in this information disclosure statement; and/or
3. listing documents including patents, publications, and other information for consideration by the Examiner, copies of which are included with this information disclosure statement;
4. listing other information for the Examiner's consideration which was cited in a communication from a foreign patent office in a counterpart foreign application, a copy of which is included with this information disclosure statement.

APPLICANTS: DALTON, James T. et al
SERIAL NO.: 10/616,500
FILED: July 10, 2003
Page 2

P-5235-US1

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

- I) Within three (3) months of filing the subject Application or entry of the subject Application into the national stage or before mailing of the first Office Action on the merits of the subject Application or a request for continued examination thereof, whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or
- II) After the period specified in (I) but before the mailing date of either a final Official Action under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311 whichever occurs first and;

1. the undersigned hereby states that each item of information listed on the Form PTO-1449 was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement or (ii) not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, not

APPLICANTS:

DALTON, James T. et al

SERIAL NO.:

10/616,500

FILED:

July 10, 2003

Page 3

P-5235-US1

known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this information disclosure statement; or

2. the undersigned hereby authorizes the Patent Office to charge the fee in the amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 05-0649.

III) After the period in (I) and (II) but before the payment of the issue fee and,

1. The undersigned hereby states:

a) that each item of information cited on the form PTO-1449 was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or

b) that no items of information contained in Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and


2. The undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 05-0649.

APPLICANTS: DALTON, James T. et al
SERIAL NO.: 10/616,500
FILED: July 10, 2003

P-5235-US1

Page 4

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.


Respectfully submitted,

Mark S. Cohen
Attorney for Applicant(s)
Registration No. 42,425

Dated: March 3, 2004

Eitan, Pearl, Latzer & Cohen Zedek, LLP.
10 Rockefeller Plaza, Suite 1001
New York, New York 10020
Tel: (212) 632-3480
Fax: (212) 632-3490



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

**Approved for use
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/616,500
		Filing Date	July 10, 2003
		First Named Inventor	DALTON, James T.
		Group Art Unit	Not yet known
		Examiner Name	Not yet known
		Attorney Docket Number	P-5234-US1
1	of	4	

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
A	10/298,229			Miller et. al.	* 11-28-2002	
B	10/270,232			Dalton et. al.	* 10-15-2002	
C	10/277,108			Dalton et. al.	* 10-23-2002	
D	10/270,233			Dalton et. al.	* 10-15-2002	
E	10/270,732			Dalton et. al.	* 10-15-2002	
F	10/371,213			Dalton et. al.	* 02-24-2003	
G	10/371,155			Dalton et. al.	* 02-24-2003	
H	10/371,209			Dalton et. al.	* 02-24-2003	
I	10/371,210			Dalton et. al.	* 02-24-2003	
J	10/359,270			Steiner et. al.	* 02-06-2003	
K	10/310,150			Steiner et. al.	* 12-05-2002	
L	6,160,011			Miller et. al.	12-12-2000	
M	6,071,957			Miller et. al.	06-06-2000	
N	6,482,861			Miller et. al.	11-19-2002	
O	6,019,957			Miller et. al.	02-01-2000	
P	6,492,554			Dalton et. al.	12-10-2002	
Q	6,569,896			Dalton et. al.	05-27-2003	
R	4,636,505			Tucker	01-13-1987	
S	4,880,839			Tucker	11-14-1989	
T	4,465,507			Konno, et al.	08-14-1984	
U	3,875,229			Gold	04-01-1975	
V	4,139,638			Neri, et al.	02-13-1979	
W	4,191,775			Glen	03-04-1980	
X	4,239,776			Glen, et al.	12-16-1980	
Y	4,386,080			Crossley, et al.	05-31-1983	
Z	4,282,218			Glen, et al.	08-14-1981	
AA	5,609,849			Kung	03-11-1997	
AB	5,162,504			Horoszewicz	11-10-1992	
AC	5,656,651			Sovak, et al.	08-12-1997	

Examiner Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not used. Include copy of this form with next communication to applicant.


¹EXAMINER, initial if reference is made to this application in next communication to applicant.
considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

number of the patient document. Kind of document. If English language Translation is attached, check here if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside the box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

U.S. PATENT AND TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 Substitute for form 1449B/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number 10/616,500	Filing Date July 10, 2003
		First Named Inventor DALTON, James T.	Group Art Unit Not yet known
		Examiner Name Not yet known	Attorney Docket Number P-5234-US1
Sheet	2	of	4

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴ (if known)			
AD	WO	02 00617		Bristol-Myers Squibb	01-03-2002	
AE	WO	01 27622		Bristol-Myers Squibb	04-19-2001	
AF	WO	01 28990		Nobex Corporation	04-26-2001	
AG	WO	01 34563		Nobex Corporation	05-17-2001	
AH	WO	03 011302		Merck & Co.	02-13-2003	
AI	WO	98 05962		Panvera Corporation	02-12-1998	
AJ	WO	98/53826		U. of Tennessee	12-3-1998	
AK	EP	0 100 172		Imperial Chemical Indust.	2-8-1984	
AL	EP	0 040 932		Imperial Chemical Indust.	12-2-1981	
AM	WO	95/19770		Sepracor Inc.	7-27-1995	
AN	EP	0 253 503		Tucker	1-20-1988	
AO	EP	000 2892		Imperial Chemical Indust.	2-6-1985	
AP	JP	52-128329	Abst	Teikoku Hormone Mfg.	10-27-1977	
AQ	JP	54-63047	Abst	Glen et al.	12-16-1980	
AR	GB	1360001		Neri et al.	3-16-1970	
AS	WO	02/016310		Dalton et al.	02-28-2002	
AT	WO	98/55153		Dalton et al.	12-10-1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 08 2004
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/616,500
				Filing Date	July 10, 2003
				First Named Inventor	DALTON, James T.
				Group Art Unit	Not yet known
				Examiner Name	Not yet known
				Attorney Docket Number	P-5234-US1
Sheet		3	of	4	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AU	Eliason et al., "High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands," Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), April 7, 2002	
	AV	Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, "Resolution of the Nonsteroidal Antiandrogen - 4'-Cyano-3-[4-fluorophenyl]sulfonyl]-2-hydroxy-2-methyl-3'-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer "	
	AW	D. McKillop, et al., "Enantioselective metabolism and pharmacokinetics of Casodex in the male rat", Xenobiotica, 1995, Vol. 25, No. 6, 623-634.	
	AX	Leonid Kirkovsky, et al., "[¹²⁵ I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer", Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sept. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163	
	AY	David T. Baird and Anna F. Glasier, "Hormonal Contraception - Drug Therapy", The New England Journal of Medicine , May 27, 1993, pp. 1543 - 1549	
	AZ	F.C. W. Wu, "Male Contraception: Current Status and Future Prospects", Clinical Endocrinology, (1988), 29, pp. 443-465	
	BA	Carl Djerassi and S.P. Leibo, "A new look at male contraception", Nature, Vol. 370, pp. 11-12	
	BB	World Health Organisation Task Force on Methods for the Regulation of Male Fertility, "Contraceptive efficacy of testosterone-induced azoospermia in normal men", The Lancet, Vol. 336, October 20, 1990, pp. 955-959 and 1517-1518	
	BC	C. G. Francisco, et al., "Long-acting contraceptive agents: testosterone esters of unsaturated acids", Steroids, January 1990, vol. 55, Butterworths	
	BD	John M. Hoberman and Charles E. Yesalis, "The History of Synthetic Testosterone", Scientific American, February 1995, pp. 76-81.	
	BE	Leonid Kirkovsky, et al., "Approaches to Irreversible non-steroidal chiral antiandrogens", Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995	
	BF	David J. Handelsman, "Bridging the gender gap in contraception: another hurdle cleared" The Medical Journal of Australia, Vol. 154, February 18, 1996, pp. 230-233.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUBSTITUTE FOR FORM 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/616,500
Filing Date	July 10, 2003
First Named Inventor	DALTON, James T.
Group Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	P-5234-US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	T ²
	BG	Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyranolo[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.
	BH	Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.
	BI	Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diakyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent; nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335,1999.
	BJ	Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK. Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem., 42: 210, 1999.
	BK	Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem., 38: 4855, 1995.
	BL	Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Commun.,244(1):1-4, 1998.
	BM	Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.
	BN	Berger et al., "Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate", Invest. Urol, (1975), 1391, 10-16

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.